Gamma-Linolensäure zur Prophylaxe und Therapie des atopischen Ekzems?

Melnik, Bodo C.

doi:10.1007/978-3-642-78163-6_20

Cited by 2 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the overall disappointing results of the present study, the positive data on subgroup analysis, recent findings on alterations of lipid mediator and cytokine production by borage oil, 17 and the excellent tolerance of the drug encourage further study of this agent as a food supplement in atopic eczema where a possible correction of the immaturity of the immune system is a major goal 18 . Furthermore, as the drug seems to act more rapidly in children and as specific defects in lipid metabolism are observed in atopic children as well as in their mothers, with decreased GLA in their breast milk, treatment of this patient group seems particularly promising.…”

Section: Discussionmentioning

confidence: 60%

Double-blind, multicentre analysis of the efficacy of borage oil in patients with atopic eczema

Henz

Jablonska²,

Kerkhof

et al. 1999

Br J Dermatol

View full text Add to dashboard Cite

Although gamma-linolenic acid (GLA) has been shown to correct deficiencies in skin lipids associated with reduced delta-6-desaturase activity which should result in improvement of dysregulation of inflammation and immunity in atopic eczema, clinical studies with evening primrose oil containing 10% GLA have yielded contradictory results. We have therefore examined the effect of a higher percentage (at least 23%) GLA-containing borage oil in adults with stable atopic eczema of moderate severity in a double-blind, multicentre study. One hundred and sixty patients were randomized to take daily either 500 mg of borage oil-containing capsules or the bland lipid miglyol as a placebo over a 24-week period. Use of topical diflucortolone-21-valerate cream was allowed as rescue medication, with the amount used until response being defined as primary, and clinical improvement as secondary efficacy criteria. Although several clinical symptoms improved compared with placebo, the overall response to borage oil did not reach statistical significance. Significant differences in favour of borage oil were, however, observed in a subgroup excluding patients who failed to show increased erythrocyte dihomo-gamma-linolenic acid levels and in whom adherence to inclusion criteria and the study protocol were questionable. GLA metabolites increased in borage oil-treated patients only, and serum IgE showed a trend to decrease on overall and subgroup analysis. No substance-related adverse effects were observed. This study shows no overall efficacy of GLA-containing borage oil in atopic eczema, with steroid use being the primary response parameter, although it suggests that a subgroup of patients may benefit from this well-tolerated treatment.

show abstract

Section: Discussionmentioning

confidence: 60%